Synthesis of the european alara network 20th workshop "alara for interventional radiology and nuclear medicine".

European ALARA network interventional radiology new radiopharmaceuticals nuclear medicine

Journal

Journal of radiological protection : official journal of the Society for Radiological Protection
ISSN: 1361-6498
Titre abrégé: J Radiol Prot
Pays: England
ID NLM: 8809257

Informations de publication

Date de publication:
01 May 2024
Historique:
medline: 2 5 2024
pubmed: 2 5 2024
entrez: 1 5 2024
Statut: aheadofprint

Résumé

The European ALARA Network regularly organises workshops on topical issues in radiation protection. The topic of the 20th workshop was: "ALARA for interventional radiology (IR) and nuclear medicine (NM)". The main objective was to examine the challenges faced when applying the optimisation principle (ALARA) in IR and NM and to consider how ALARA could be better implemented for patient and staff exposures. This memorandum provides a synthesis of the workshop sessions and recommendations arising from the working groups discussion. Parallels are drawn with the recommendations coming from the 13th EAN workshop on "ALARA and the medical sector" (2011) to consider how the optimisation challenges in IR and NM have evolved over the past decade.
Current levels of exposure are presented along with operational practice and the challenges and opportunities for improvement, both in monitoring and practice. Whilst RP challenges remain, the application of ALARA appears more established in IR compared with experiences reported in 2011. The application of ALARA to emerging technologies in the NM setting is in need of further development to ensure that radiation protection is considered at all stages in the development process of new radiopharmaceuticals. Besides technical and operational aspects, the importance of education and training, human factors and , broadly, the radiation protection 'culture' were deemed fundamental to the success of the application of ALARA and where further emphasis is needed. All concerned parties, MPEs, RPEs, medical staff, manufacturers and regulators have a role to play in the application of ALARA and this is discussed in the memorandum. 
Many of the recommendations from the 13th EAN workshop remain applicable today and overlap with the recommendations arising from the 20th workshop. This should prompt attention given that the use of IR and the development of novel radiopharmaceuticals for NM is only anticipated to increase with time.

Identifiants

pubmed: 38692267
doi: 10.1088/1361-6498/ad460d
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024 Society for Radiological Protection. Published on behalf of SRP by IOP Publishing Limited. All rights reserved.

Auteurs

Sylvain Andresz (S)

Nuclear Protection Evaluation Centre, Fontenay-aux-Roses, FRANCE.

Penelope J Allisy-Roberts (PJ)

EFOMP, Paris, FRANCE.

Sotirios Economides (S)

Greek Atomic Energy Commission, Athens, GREECE.

Julie Morgan (J)

UK Health Security Agency North of England, Leeds, Leeds, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.

Franz Kabrt (F)

Austrian Agency for Health and Food Safety GmbH, Vienna, AUSTRIA.

Sharan Packer (S)

The Society for Radiological Protection, Leeds, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.

Arturo Perez Mulas (AP)

Spanish Nuclear Safety Authority, Madrid, SPAIN.

Andy Rogers (A)

Medical Physics and Clinical Engineering, University Hospital NHS Trust, Nottingham, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND.

Caroline Schieber (C)

Nuclear Protection Evaluation Centre, Fontenay-aux-Roses, Île-de-France, FRANCE.

Nicolas Stritt (N)

Swiss Federal Office of Public Health (SFOPH), Bern, SWITZERLAND.

Fernand Vermeersch (F)

Studiecentrum voor Kernenergie, Mol, BELGIUM.

Classifications MeSH